SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Treasury Stock, Receivables and Doubtful Accounts and Deferred Revenue (Details) - USD ($)		3 Months Ended
		Mar. 31, 2018		Mar. 31, 2017	Dec. 31, 2017
Treasury Stock [Abstract]
Treasury stock purchased (in shares)		0		4,260
Average price of share (in dollars per share)				$ 52.07
Receivables and Doubtful Accounts [Abstract]
Accounts receivable		$ 19,165,670	[1]		$ 4,655,105
Deferred Revenue [Abstract]
Deferred revenue		135,000			6,400,000
Adjustments / Effect of Change Higher / (Lower) [Member] | ASU 2014-09 [Member]
Receivables and Doubtful Accounts [Abstract]
Accounts receivable		7,045,000
Nonrefundable Upfront Product License Fees [Member]
Deferred Revenue [Abstract]
Deferred revenue		35,000
Milestone Payment Due Foreign Tax Withholding [Member]
Deferred Revenue [Abstract]
Deferred revenue		100,000
Endo [Member]
Receivables and Doubtful Accounts [Abstract]
Accounts receivable		$ 19,165,670			4,655,105
Deferred Revenue [Abstract]
Deferred revenue					(6,400,000)
Endo [Member] | ASU 2014-09 [Member]
Receivables and Doubtful Accounts [Abstract]
Accounts receivable					12,300,000
Deferred Revenue [Abstract]
Deferred revenue					(100,000)
Endo [Member] | Adjustments / Effect of Change Higher / (Lower) [Member] | ASU 2014-09 [Member]
Receivables and Doubtful Accounts [Abstract]
Accounts receivable	[2]				7,600,000
Deferred Revenue [Abstract]
Deferred revenue	[3]				$ 6,300,000

[1] As of January 1, 2018, the Company adopted the requirements of ASC 606 using the modified retrospective adoption method, and as a result, there is a lack of comparability of certain amounts to the prior periods presented. See Note 2 for additional discussion.

[2] This adjustment represents the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.

[3] Represents the remaining deferred revenue balance of the prepaid mark-up on cost of goods sold based on sales by non-affiliated sublicensees of Endo outside of the U.S.